215168-76-6

Basic information

• Product Name: (R)-N-(tert-butyloxycarbonyl)-1-(3-aminophenyl)-3-(3,4-dimethoxyphenyl)propan-1-ol
• Synonyms: (R)-N-(tert-butyloxycarbonyl)-1-(3-aminophenyl)-3-(3,4-dimethoxyphenyl)propan-1-ol
• CAS NO: 215168-76-6
• Molecular Weight: 387.476
• Mol File: 215168-76-6.mol

Chemical Properties

• CAS DataBase Reference: (R)-N-(tert-butyloxycarbonyl)-1-(3-aminophenyl)-3-(3,4-dimethoxyphenyl)propan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-(tert-butyloxycarbonyl)-1-(3-aminophenyl)-3-(3,4-dimethoxyphenyl)propan-1-ol(215168-76-6)
• EPA Substance Registry System: (R)-N-(tert-butyloxycarbonyl)-1-(3-aminophenyl)-3-(3,4-dimethoxyphenyl)propan-1-ol(215168-76-6)

Safety Data

• Hazardous Substances Data: 215168-76-6(Hazardous Substances Data)

Upstream product

• 952578-03-9 (E)-1-(3-aminophenyl)-3-(3,4-dimethoxyphenyl)prop-2-en-1-one 
• 99-03-6 1-(3-aminophenyl)ethanone 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 215168-74-4 1-(3-aminophenyl)-3-(3,4-dimethoxyphenyl)-1-propanone 
• 75573-20-5 (2E)-3-(3,4-dimethoxyphenyl)-1-(3-nitrophenyl)-2-propen-1-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 215168-75-5 tert-butyl (3-(3-(3,4-dimethoxyphenyl)propanoyl)phenyl)carbamate 
• 121-89-1 3-Nitroacetophenone 

Downstream Products

• 919519-98-5 C₃₈H₅₅N₃O₁₀ 
• 1431530-93-6 (R)-3-(3,4-dimethoxyphenyl)-1-(3-((2,2-dimethyl-4,15-dioxo-3,8,11-trioxa-5,14-diazahexadecan-16-yl)oxy)phenyl)propyl (S)-1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate 
• 195513-96-3 SLF 
• 215168-85-7 (1R)-1-[3-N-(tert-butyloxycarbonyl)aminophenyl]-3-(3,4-dimethoxyphenyl)-1-propanyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarboxylate 

Relevant articles and documents

RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have grea

Targeted Covalent Inhibition of Plasmodium FK506 Binding Protein 35

FK506-binding protein 35, FKBP35, has been implicated as an essential malarial enzyme. Rapamycin and FK506 exhibit antiplasmodium activity in cultured parasites. However, due to the highly conserved nature of the binding pockets of FKBPs and the immunosuppressive properties of these drugs, there is a need for compounds that selectively inhibit FKBP35 and lack the undesired side effects. In contrast to human FKBPs, FKBP35 contains a cysteine, C106, adjacent to the rapamycin binding pocket, providing an opportunity to develop targeted covalent inhibitors of Plasmodium FKBP35. Here, we synthesize inhibitors of FKBP35, show that they directly bind FKBP35 in a model cellular setting, selectively covalently modify C106, and exhibit antiplasmodium activity in blood-stage cultured parasites.

Synthesis and activity of bivalent FKBP12 ligands for the regulated dimerization of proteins

The total synthesis and in vitro activities of a series of chemical inducers of dimerization (CIDs) is described. The use of small-molecule CIDs to control the dimerization of engineered FKBP12-containing fusion proteins has been demonstrated to have broad utility in biological research as well as potential medical applications in gene and cell therapies. The facility and flexibility of preparation make this new class of wholly synthetic compounds exceptionally versatile tools for the study of intracellular signaling events mediated by protein-protein interactions or protein localization. While some congeners possess potency comparable to or better than the first generation natural product-derived CID, FK1012, structure-activity relationships are complex and underscore the need for application-specific compound optimizations. Copyright (C) 1998 Elsevier Science Ltd.